| Autor: |
Andrés Gómez-De León, Ana L. Varela-Constantino, Perla R. Colunga-Pedraza, Alexia Sánchez-Arteaga, Valeria García-Zárate, Anna Cecilia Rodríguez-Zúñiga, Nereida Méndez-Ramírez, Olga G. Cantú-Rodríguez, César H. Gutiérrez-Aguirre, Luz Tarín-Arzaga, Elías E. González-López, José Carlos Jaime-Pérez, David Gómez-Almaguer |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Clinical Lymphoma Myeloma and Leukemia. 22:883-893 |
| ISSN: |
2152-2650 |
| DOI: |
10.1016/j.clml.2022.07.014 |
| Popis: |
B-cell acute lymphoblastic leukemia is frequent in Hispanic adolescents and young adults. Outcomes of implementation of pediatric-inspired regimens in low-and middle-income countries are not well known.In this study we treated 94 adolescents and young adults with a local BFM regimen designed to be affordable with the use of native L-asparaginase and mitoxantrone administered in an outpatient fashion, and the of BCR/ABL and measurable residual disease (MRD) determined by high sensitivity flow cytometry for risk stratification.Induction mortality was 11%; 25% of patients had to abandon treatment or be transferred to another health system. Two-year overall (OS) and event free survival (EFS) were 61.5% and 49.8%, MRD-negative patients had a 24-month OS of 85.6% vs. 69.6% (p = .024) and EFS of 76% vs. 45.5% (p = .004). Patients older than 40 years and those who abandoned treatment had worse EFS. Overall drug costs in our regimen were 52% lower than those of CALGB10403. The treatment of AYAs with ALL with an outpatient focus was implemented successfully at a reduced cost. Genetic risk assessment, treatment abandonment and lack of access to novel therapies remain major barriers for improving outcomes. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect